Evidence map›Paper›PMID 28448721›Full record

Trial reportAmerican journal of respiratory and critical care medicine2017

Triplicate Sputum Cultures for Efficacy Evaluation of Novel Antituberculosis Regimens.

Andreas H Diacon, Elana van Brakel, Nacer Lounis, Paul Meyvisch, Ben Van Baelen, Tine De Marez, Eilidh Jenkins, Brian Dannemann

Abstract readLetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andreas H Diacon1 University of Stellenbosch Cape Town, South Africa.
Elana van Brakel1 University of Stellenbosch Cape Town, South Africa.
Nacer Lounis2 Janssen Research and Development Beerse, Belgium.
Paul Meyvisch2 Janssen Research and Development Beerse, Belgium.
Ben Van Baelen2 Janssen Research and Development Beerse, Belgium.
Tine De Marez3 Janssen Research & Development, LLC Titusville, New Jersey and.
Eilidh Jenkins4 Janssen UK High Wycombe, United Kingdom.
Brian Dannemann3 Janssen Research & Development, LLC Titusville, New Jersey and.

Funding

Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, MultipleAdultAgedAged, 80 and overAntitubercular AgentsDouble-Blind MethodFemaleHumansMaleMiddle AgedMycobacterium tuberculosisSputumTuberculosis, PulmonaryAntitubercular Agents

Identifiers

PMID28448721
PMCPMC5803658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.